E3 PreliminaryPreliminaryPEM not requiredReview-NarrativePeer-reviewedMachine draft
alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action.
Meadows, L M, Walther, P, Ozer, H · Seminars in oncology · 1991
Quick Summary
This study tested a cancer treatment combining two drugs (5-fluorouracil and interferon alfa-2b) in 17 patients. One side effect observed was chronic fatigue syndrome, which forced doctors to reduce the interferon dose in some patients. The study found the drug combination showed promise against certain cancers, but it also caused significant side effects including fatigue, mouth sores, and other complications.
Why It Matters
This study is relevant to ME/CFS research because it documents chronic fatigue syndrome as a direct iatrogenic (treatment-induced) outcome in cancer patients receiving interferon alfa-2b therapy. Understanding how exogenous interferon triggers fatigue may provide mechanistic insights into ME/CFS pathophysiology, particularly regarding interferon-alpha's role in immune dysregulation and post-exertional malaise.
Observed Findings
- Chronic fatigue syndrome developed in patients receiving high-dose interferon alfa-2b, requiring dose reduction.
- Interferon alfa-2b administration caused a 16-fold elevation in 5-FU plasma levels within 1 hour, sustained for ≥24 hours.
- Mucositis occurred in 10 of 17 patients (59%) at 2 weeks, necessitating therapy interruption and dose reduction.
- Five objective responses were observed (2 complete, 2 partial, 1 minor) in patients with gastrointestinal malignancy.
- No toxic deaths occurred, but multiple grade 2–3 toxicities were documented including hepatic and renal dysfunction, alopecia, diarrhea, and confusion.
Inferred Conclusions
- Interferon alfa-2b potentiates 5-FU bioavailability through a mechanism independent of IL-6 upregulation.
- Chronic fatigue syndrome represents a dose-limiting toxicity of high-dose interferon alfa-2b warranting careful patient monitoring and dose adjustment.
- The 5-FU/interferon alfa-2b combination warrants advancement to phase II trials for GI malignancies despite significant toxicity burden.
Remaining Questions
- What is the biological mechanism by which interferon alfa-2b elevates 5-FU plasma levels if not through IL-6 signaling?
- Does the fatigue induced by interferon alfa-2b resemble ME/CFS phenotypically, or is it qualitatively different from post-exertional malaise and post-viral sequelae?
What This Study Does Not Prove
This study does not prove that interferon alfa-2b causes ME/CFS in the general population or that all patients receiving interferon develop post-exertional malaise. The fatigue observed was associated with high-dose oncologic therapy in a small, acutely ill population and may not generalize to the chronic multifactorial disease process in ME/CFS. Correlation between interferon exposure and fatigue does not establish the underlying biological mechanisms of ME/CFS.
Tags
Symptom:Fatigue
Biomarker:Cytokines
Method Flag:No ControlsSmall SampleExploratory Only
Metadata
- PMID
- 1948133
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →